ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
XTL Biopharmaceuticals Ltd

XTL Biopharmaceuticals Ltd (XTLB)

2.81
0.11
(4.07%)
At close: March 28 04:00PM
2.81
0.11
( 4.07% )
After Hours: 05:24PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.81
Bid
2.82
Ask
2.89
Volume
233,228
2.56 Day's Range 2.83
0.00 52 Week Range 0.00
Market Cap
Previous Close
2.70
Open
2.64
Last Trade Time
17:24:08
Financial Volume
$ 627,214
VWAP
2.6893
Average Volume (3m)
-
Shares Outstanding
-
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About XTL Biopharmaceuticals Ltd

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic ... XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Ramat Gan, Center, Isr
Founded
1970
XTL Biopharmaceuticals Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XTLB. The last closing price for XTL Biopharmaceuticals was $2.70. Over the last year, XTL Biopharmaceuticals shares have traded in a share price range of $ 0.00 to $ 0.00.

XTL Biopharmaceuticals currently has 0 shares outstanding.

XTLB Latest News

XTL To Aquire The Social Proxy

expands its IP portfolio to AI Web Data The Social Proxy is a web data AI companydeveloping and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   Report of Foreign Private Issuer   Pursuant to Rule 13a-16 or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   Report of Foreign Private Issuer   Pursuant to Rule 13a-16 or...

XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main...

XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel

Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   Report of Foreign Private Issuer   Pursuant to Rule 13a-16 or...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.09
(57.99%)
2.52M
GRTXGalera Therapeutics Inc
$ 0.171
(22.14%)
749.86k
SBFMSunshine Biopharma Inc
$ 0.0736
(21.65%)
22.96M
XLOXilio Therapeutics Inc
$ 1.26
(16.67%)
1.07M
NUWENewellis Inc
$ 0.4002
(12.57%)
33.56k
XTKGX3 Holdings Company Ltd
$ 0.66
(-33.34%)
1.16M
NDRAENDRA Life Sciences Inc
$ 0.45
(-22.41%)
97.24k
NVVENuvve Holding Corporation
$ 0.875
(-20.45%)
96.15k
APLTApplied Therapeutics Inc
$ 5.80
(-14.71%)
228.8k
APLMApollomics Inc
$ 0.641
(-14.53%)
25.47k
SBFMSunshine Biopharma Inc
$ 0.0736
(21.65%)
22.96M
CRKNCrown Electrokinetics Corporation
$ 0.0609
(1.67%)
5.64M
AAPLApple Inc
$ 171.23
(-0.15%)
3.52M
JAGXJaguar Health Inc
$ 0.0877
(-2.45%)
2.63M
MSFTMicrosoft Corporation
$ 420.04
(-0.16%)
2.59M

XTLB Discussion

View Posts
Monksdream Monksdream 3 days ago
XTLB new 52 hi
👍️0
Pedro2004 Pedro2004 3 days ago
Schwabb won't let me short companies likes this.
👍️0
Pedro2004 Pedro2004 3 days ago
Nice little pump and dump today.
👍️0
Pedro2004 Pedro2004 3 days ago
Another scam Israeli company.
👍️0
Monksdream Monksdream 6 days ago
XTLB new 52 hi
👍️0
Zardiw Zardiw 1 week ago
$XTLB Chart from #DDAmanda - #1 Stock Screener :

Scans are preset. Push a Button. Find Winners Early:



Z
👍️0
Monksdream Monksdream 1 week ago
XTLB new 52 week hi
👍️0
Awl416 Awl416 1 week ago
XTL To Aquire The Social Proxy
👍️0
stock1ace1 stock1ace1 1 week ago
27k vol unusual vol 2 days before run looks like some insiders knew the news was coming …
👍️0
stock1ace1 stock1ace1 3 years ago
running !
👍️0
trendzone trendzone 3 years ago
Halted shorts about to get ripped apart
👍️0
stock1ace1 stock1ace1 3 years ago
News Watch Latest Pr Co Seeking Partnership/Merger

The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.
👍️0
alchemytrader alchemytrader 3 years ago
volume
👍️0
stock1ace1 stock1ace1 3 years ago
$3.62 Macd crossover #bullish -> https://stockcharts.com/h-sc/ui?s=Xtlb
👍️0
stock1ace1 stock1ace1 3 years ago
XTLb is continually looking for late stage products to in-license or acquire. In addition, we are pursuing partnerships for the development and marketing of our products internationally. If your company has interest in discussing a potential business collaboration with XTL, please contact our business development department at: bd@xtlbio.com or call us at +972 9 955 7080.
👍️0
stock1ace1 stock1ace1 3 years ago
Company is seeking merger / partnership The Company is expanding its IP portfolio surrounding hCDR1 and has decided, at this time, to explore cooperation with a strategic partner in order to execute its clinical trials. In parallel, the Company will look to expand and identify additional assets to add to XTL’s portfolio.
👍️0
ClayTrader ClayTrader 3 years ago
* * $XTLB Video Chart 03-05-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
odds_are odds_are 3 years ago
Thanks for the link. Other boards seem to be clueless as to why the sharp increase in price.$XTLB
👍️0
AlphaStockNews AlphaStockNews 3 years ago
$XTLB is screaming for the top after a recent report shows massive growth in the company's target market. This is a clear acquisition target! https://cnafinance.com/xtlb-stock-xtl-biopharmaceuticals-is-rocketing/
👍️0
Awl416 Awl416 3 years ago
Good lord
👍️0
wesley_ wesley_ 4 years ago
$1.70 nice
👍️0
PennyStock Alert PennyStock Alert 5 years ago
http://barchart.com/quotes/stocks/XTLBY
👍️0
ClayTrader ClayTrader 6 years ago
* * $XTLB Video Chart 05-07-18 * *

Link to Video - click here to watch the technical chart video

👍️0
Joecanada13 Joecanada13 6 years ago
Boom!!!
👍️0
Tdash Tdash 7 years ago
hmmm
👍️0
Awl416 Awl416 7 years ago
55k
👍️0
PAC PAC 7 years ago
What was the volume AH yesterday?
👍️0
europtiger europtiger 7 years ago
There is some 3,50 Gifts
👍️0
europtiger europtiger 7 years ago
Woow afterhour
👍️0
stocktrademan stocktrademan 8 years ago
XTLB bullish 1.22




👍️0
Yo-Yo Yo-Yo 8 years ago
Whose driving this bus today, any catalyst here? GLTA!!!
👍️0
fortunebuilder1959 fortunebuilder1959 9 years ago
Will def have this on my radar; ready to jump in with any momentum....
👍️0
Arizzle Arizzle 9 years ago
I must have missed the pump too
👍️0
marcusjtrader marcusjtrader 9 years ago
XTLB is a clear pump and dump based on charting. The company hasn't had any news in over a month. Claim your shares to short now.
👍️0
Arizzle Arizzle 9 years ago
Multi-day run?
👍️0
jcseattle jcseattle 9 years ago
http://finance.yahoo.com/news/xtl-biopharmaceuticals-further-strengthens-team-120000879.html
👍️0
jcseattle jcseattle 9 years ago
(XTLB) Very good time to short it.
👍️0
AntiOne AntiOne 9 years ago
Boom...another pick skyrocket from BackPackOfStock
👍️0
Tradescott818 Tradescott818 9 years ago
No idea
👍️0
javier1973 javier1973 9 years ago
What happen?.
👍️0
Tradescott818 Tradescott818 9 years ago
Wowwowowowowowowoowow
👍️0
AntiOne AntiOne 10 years ago
Just picked a few shares....heard rumblings
👍️0
surf1944 surf1944 10 years ago
8:02AM XTL Biopharma announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, (XTLB) 2.73 : Co announced it has signed a licensing agreement with Yeda Research and Development Company to develop hCDR1, a Phase II-ready asset for the treatment of Systemic Lupus Erythematosus.

Two placebo controlled Phase I trials and a placebo controlled Phase II trial were conducted by Teva Pharmaceutical (TEVA) which had previously in-licensed hCDR1 from Yeda. The Phase I and Phase II studies consisted of over 400 patients, demonstrating that hCDR1 is well tolerated by patients and has a favorable safety profile. The PRELUDE trial did not achieve its primary efficacy endpoint based on the SLEDAI scale, resulting in Teva returning the asset to Yeda. However, the PRELUDE trial showed encouraging results in its secondary clinical endpoint, the BILAG index, and, in fact, the 0.5 mg weekly dose showed a substantial effect. Multiple post-hoc analyses also showed impressive results for this dose using the BILAG index. Such dose will be the focus of the clinical development plan moving forward.

The FDA has since directed that the primary endpoint in future trials for Lupus therapies, including those for hCDR1, should be based on either the BILAG index or the SLE Responder Index. Given the FDA's recommendation and the positive findings from the PRELUDE trial, XTL intends to initiate a new Phase II clinical trial, which will include the 0.5 mg (and a 0.25 mg) weekly dose of hCDR1.

👍️0
Renee Renee 11 years ago
XTLBY changed to XTLB and uplisted to the Nasdaq NCM:

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/12/2013&mkt_ctg=NON-OTCBB
👍️0
Renee Renee 11 years ago
XTLBY: 1-10 R/S concurrent with a ratio change. The ADR Ratio will change from [ one(1) ADS: two (2) Ordinary Share] to a new ratio of [ one (1) ADS: twenty (20) Ordinary Share]. Holders of XTL BioPharmaceuticals will be required on a mandatory basis to surrender their Old ADSs to BNY Mellon in exchange for the New ADSs. ONly whole DRs will be distributed.

http://www.otcbb.com/asp/dailylist_detail.asp?d=10/03/2012&mkt_ctg=NON-OTCBB
👍️0
Eugene_2009 Eugene_2009 12 years ago
Hello,
Is there more information over XTLBY?
👍️0
Eugene_2009 Eugene_2009 12 years ago
http://barchart.com/quotes/stocks/XTLBY
👍️0
paulbk paulbk 12 years ago
Hello to you as well. Sounds like the adjustment has to be enough to ensure a Nasdaq listing which I guess means at least 5 dollars. Good luck to you.
👍️0
odds_are odds_are 12 years ago
Hi paulbk - nice to know someone else is still keeping up with this stock! Although this is my first post to this board I am a long time holder (a very long time...)

At first applying to be listed on the NASDAQ sounds like a good thing. It's just the ADR ratio adjustment I am not sure about.
👍️0
paulbk paulbk 12 years ago
You don't hear anything for years and suddenly this:

http://www.sacbee.com/2012/06/04/4537009/xtl-biopharmaceuticals-files-application.html

"adjusting" the price of the ADR means an R/S basically. Not sure if that will mean a loss or not. It's possible this will just trade as flat as it always does afterwards. Might even go up,GLTA
👍️0

Your Recent History

Delayed Upgrade Clock